BRL-501 / BRL Medicine - LARVOL DELTA

2022-BRL-501: Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Shanghai Changzheng Hospital | Trial primary completion date: May 2026 ➔ Aug 2026

Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • FOLH1

2022-BRL-501: Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Shanghai Changzheng Hospital | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: May 2025 ➔ May 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • FOLH1

The safety and efficacy evaluation of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment of refractory castration resistant prostate cancer (ESMO 2025) - P1 | "Here, we have designed an enhanced autologous CAR-T therapy (BRL-501), which targets prostate cancer-specific membrane antigens (PSMA)and is designed to secrete cytokines, thereby activating the immune system and enhancing the overall anti-tumor response...Shancheng Ren. Funding National Natural Science Foundation of China(82125025) Shanghai Shenkang Hospital Development Center (SHDC2022CRT005)."

CAR T-Cell Therapy • Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor